November 19, 2024 02:17 PM EST
Pharma
Law

BeiGene set­tles fi­nal suit over fu­ture Brukin­sa gener­ics

Max Bayer

Pharma Reporter

BeiGene has set­tled a law­suit with gener­ics man­u­fac­tur­er MSN Phar­ma­ceu­ti­cals, re­solv­ing all cas­es as­so­ci­at­ed with the en­try of Brukin­sa al­ter­na­tives in the US.

The phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times